Helixgate https://validator.w3.org/feed/docs/rss2.html STAT+: Kennedy names interim surgeon general amid vacancies atop health department Home STAT+: 3 burning questions senators had for the NIH director #ASCO26: Merck partner Kelun outlines Phase 3 lung cancer success in China study How To Shine As Biotech Comes Back From the Brink Bio-IT World Celebrates 25 Years with Opening Plenary on Rare Disease Challenges and Opportunities AI Model Offers Map of How Genes Work Together in Different Cellular Contexts Guarding biotech from China and big bets in longevity How a group of biotechs ran a covert campaign to push out the FDA commissioner Update: Reversal after 20 deaths allows new Japan patients to take Amgen’s rare disease drug Tavneos Chutes & Ladders—Former FDA leader takes new biotech Turn STAT+: RFK Jr.’s screen time warning RA Capital banks $75M for a biotech SPAC China’s drugmakers to take the stage at #ASCO26 Novel regulatory science considerations in osteosarcoma: the imperative for regulatory flexibility to meet critical unmet patient and clinical needs BioMarin notches win in study that could expand use of top-selling medicine Roche licensing pact clears generic drugmakers to manufacture antiviral flu drug BioMarin to seek further approval of Voxzogo in form of short stature Incyte signs AI deals with Genesis Molecular AI, Edison Scientific Live: Senate committee questions NIH director on 2027 budget BMS eyes new campus in Texas; Novartis looks to evict tenant at Slovenian campus Lilly’s triple agonist shows bariatric surgery–like weight loss results How Florida hospitals won big in Medicaid funds (just in time) Vaxart seeks shareholder support as battle over stock split brews Lilly, BMS, Incyte strike deals to keep biopharma’s AI integration rolling Lilly’s triple agonist still leads among late-stage obesity assets STAT+: Lilly’s ‘triple-G’ drug leads to bariatric-surgery levels of weight loss in trial I&I biotech cAMPfield attracts top-tier investors in $180M Series A Inside Germany’s biotech capital infrastructure and innovation engine The next big pharma company will come from China Opinion: STAT+: Dark times ahead at the FDA Congressional Democrats try to force a vote to end Medicare AI prior authorization pilot Smile Please: Wisconsin Welcomes FUJIFILM Cellular Dynamics New Headquarters HELIX AI Model Accurately Predicts RNA Splicing, Unlocks Precision Medicine Are ‘AI co-scientist’ tools actually useful for scientists? STAT+: Pioneering trial for treating genetic disease before birth nears reality Lilly and Engage Bio tie the knot with $202M acquisition Biopharma professionals increasingly accept underemployment Opinion: I saw Ebola as both doctor and patient. I wish people cared more about the Africans I worked alongside STAT+: Kennedy fires two leaders on preventive services task force Standardizing Cell Therapy Production With Technology Facelift University of Dundee leads effort to tackle ‘cruel’ disease  After raising $800M, Parabilis seeks an IPO to pursue ‘undruggable’ targets Bristol Myers deepens AI investment with Anthropic deal FDA sends warning letter after Chinese supplier breaks GLP-1 import restrictions Pfizer’s next-gen pneumonia shot beats Prevnar 20; Relay targets $175M MIT scientists discover amino acid that helps the gut heal itself De novo design of miniproteins targeting GPCRs Real-time volumetric imaging of cells and molecules in deep tissues with Takoyaki ultrasound AI-guided redesign of laboratory-evolved reverse transcriptases enhances prime editing